Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Finished Goods (2024 - 2025)

Eton Pharmaceuticals' Finished Goods history spans 2 years, with the latest figure at $6.6 million for Q4 2025.

  • On a quarterly basis, Finished Goods fell 7.84% to $6.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.6 million, a 7.84% decrease, with the full-year FY2025 number at $6.6 million, down 7.84% from a year prior.
  • Finished Goods hit $6.6 million in Q4 2025 for Eton Pharmaceuticals, down from $7.2 million in the prior quarter.
  • Over the last five years, Finished Goods for ETON hit a ceiling of $7.2 million in Q4 2024 and a floor of $6.6 million in Q4 2025.